Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2019 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland

Received European approval to ship Annamycin into Poland to start treating patients HOUSTON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the...
January 03, 2019 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate

HOUSTON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
December 11, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018

HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
December 06, 2018 16:05 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 2018

HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
December 06, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug

HOUSTON, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
December 04, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces Breakthrough Discovery for its WP1066

WP1066 shown to counteract resistance to checkpoint blockades HOUSTON, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
November 28, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces New Data Further Supporting Its Lead Drug for Treating Pancreatic Cancer

WP1732 shown to accumulate beneficially in pancreas HOUSTON, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
November 15, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Requests FDA Meeting Regarding IND for New Cancer Drug

Testing confirms ability of WP1732 to target pancreatic cancer HOUSTON, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
November 13, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018

HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
November 08, 2018 07:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122

Documented potential for drug candidate with characteristics like WP1122 to reverse immune suppression HOUSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX)...